Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Rating of “Moderate Buy” by Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has been assigned an average recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $9.27.

A number of equities research analysts recently weighed in on HCAT shares. Canaccord Genuity Group dropped their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 21st. Wells Fargo & Company cut their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Piper Sandler reduced their price target on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Stephens dropped their price objective on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, March 6th. Finally, KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price on the stock in a report on Wednesday, January 8th.

Insider Activity at Health Catalyst

In other Health Catalyst news, General Counsel Benjamin Landry sold 13,827 shares of the company’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total transaction of $62,912.85. Following the sale, the general counsel now directly owns 160,437 shares of the company’s stock, valued at approximately $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the sale, the chief operating officer now owns 91,253 shares of the company’s stock, valued at approximately $685,310.03. This represents a 5.40 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,530 shares of company stock valued at $299,572. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently modified their holdings of HCAT. Quest Partners LLC acquired a new position in Health Catalyst during the third quarter worth approximately $34,000. Intech Investment Management LLC acquired a new position in shares of Health Catalyst during the 3rd quarter worth approximately $145,000. Fred Alger Management LLC bought a new stake in Health Catalyst in the 3rd quarter valued at $6,858,000. Centiva Capital LP acquired a new stake in Health Catalyst during the 3rd quarter valued at $324,000. Finally, Portolan Capital Management LLC bought a new position in Health Catalyst during the third quarter worth $5,402,000. 85.00% of the stock is owned by institutional investors.

Health Catalyst Price Performance

Shares of HCAT stock opened at $4.01 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 12 month low of $3.72 and a 12 month high of $9.24. The firm has a market cap of $281.55 million, a price-to-earnings ratio of -2.97 and a beta of 1.43. The stock has a 50-day moving average price of $4.89 and a 200 day moving average price of $6.72.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.